Pabinger, I. and Schneider, B. (1996) Thrombotic Risk in Hereditary Antithrombin III, Protein C, or Protein S Deficiency. A Cooperative, Retrospective Study. Gesellschaft fur Thromboseund Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology, 16, 742-748.
https://doi.org/10.1161/01.ATV.16.6.742

has been cited by the following article:

• TITLE: Multiple Major Thrombo-Embolic Events, including Stroke, in a Patient with Combined Congenital Anti-Thrombin III Deficiency and MTHFR Homozygous Mutation

  AUTHORS: Islam I. Zaid, Nora I. Abbas, Ehab Shaker, Foad Abd-Allah

  KEYWORDS: Thrombophilia, Thrombosis, Congenital AT III Deficiency, Stroke, Acute Coronary Syndrome, Deep Venous Thrombosis, Acute Limb Ischemia

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.7 No.3, March 27, 2017

  ABSTRACT: We report a case of a young male patient suffering from congenital Anti-Thrombin III (AT III) deficiency, presented with four major thrombotic events. These events were acute coronary syndrome (Non-ST elevation myocardial infarction), cerebral infarction, peripheral acute upper limb (UL) ischemia and bilateral extensive deep venous thrombosis. The latter two developed despite that the patient was receiving full anticoagulation therapy. His International normalized ratio (INR) was 2.5. Eventually, the patient developed pulmonary embolism and died. He had a prominent family history of thrombotic events. Screening for AT III deficiency in young patients with thrombotic event (thrombophilia) is essential especially those having family history of the latter. This is justified as thrombotic events may occur in up to 80% of these patients. Our patient with 4 major thrombotic events ending in fatality in less than 1 month deserves the nomenclature.